ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS

NCT03462498 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

3008

Enrollment

OTHER

Sponsor class

Conditions

Acute Coronary Syndrome
Acute Myocardial Infarction
Coronary Artery Disease
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors

Interventions

DRUG: 1-months DAPT
DRUG: 12-month DAPT

Sponsor

Kyoto University, Graduate School of Medicine